SCYNEXIS, Inc. Current Income Tax Expense (Benefit)
SCYNEXIS, Inc. (SCYX) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-04
- SCYNEXIS, Inc. current income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SCYNEXIS, Inc. current income tax expense (benefit) for fiscal 2024 was $151.00K, a 9.42% increase from fiscal 2023.
- SCYNEXIS, Inc. current income tax expense (benefit) for fiscal 2023 was $138.00K.
- SCYNEXIS, Inc. current income tax expense (benefit) for fiscal 2022 was -$4.70M.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-04 |
| 2024-12-31 | $151.00K 10-K · filed 2026-03-04 |
| 2023-12-31 | $138.00K 10-K · filed 2025-03-12 |
| 2022-12-31 | -$4.70M 10-K · filed 2024-03-28 |
| 2021-12-31 | -$3.09M 10-K · filed 2023-03-31 |
| 2020-12-31 | -$3.15M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |